Prosecution Insights
Last updated: November 18, 2026
Application No. 18/349,071

RAPID, NON-INVASIVE DETECTION AND SERIAL MONITORING OF INFECTIONS IN SUBJECTS USING MICROBIAL CELL-FREE DNA SEQUENCING

Non-Final OA §101§102§103
Filed
Jul 07, 2023
Priority
Jan 11, 2021 — provisional 63/136,060 +2 more
Examiner
BAUSCH, SARAE L
Art Unit
1699
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Karius Inc.
OA Round
1 (Non-Final)
30%
Grant Probability
At Risk
1-2
OA Rounds
75%
With Interview

Examiner Intelligence

Grants only 30% of cases
30%
Career Allowance Rate
182 granted / 615 resolved
-30.4% vs TC avg
Strong +45% interview lift
Without
With
+45.2%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
50 currently pending
Career history
680
Total Applications
across all art units

Office Action

§101 §102 §103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Due to the amendment to the claims, the restriction requirement among group I and group II has been withdrawn. Claims 74-93 are under examination. Priority Applicant’s claim for the benefit of a prior-filed application under 35 U.S.C. 119(e) or under 35 U.S.C. 120, 121, 365(c), or 386(c) is acknowledged. Applicant has not complied with one or more conditions for receiving the benefit of an earlier filing date under 35 U.S.C. 119 (e) as follows: The later-filed application must be an application for a patent for an invention which is also disclosed in the prior application (the parent or original nonprovisional application or provisional application). The disclosure of the invention in the parent application and in the later-filed application must be sufficient to comply with the requirements of 35 U.S.C. 112(a) or the first paragraph of pre-AIA 35 U.S.C. 112, except for the best mode requirement. See Transco Products, Inc. v. Performance Contracting, Inc., 38 F.3d 551, 32 USPQ2d 1077 (Fed. Cir. 1994). The disclosure of the prior-filed application, Application No. 63/136060 and 63/136076 fails to provide adequate support or enablement in the manner provided by 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph for one or more claims of this application. ‘060 does not provide support for Bartonella bacteria, threshold limits, specific treatment and removal of prosthetic valve. ‘076 does not provide support for determining threshold levels, threshold limits, specific antibiotic therapy recited in claim 87, or removal of prosthetic value. As such the priority date for claims 74-93 for the instant application is 01/10/2022. Claim Rejections - 35 USC § 101 35 U.S.C. 101 reads as follows: Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title. Claims 74-86, 89-93 are rejected under 35 U.S.C. 101 because the claimed invention is directed to an abstract idea and law of nature without significantly more. The claims recite an abstract idea. Claim 74 and 89 recites identifying prosthetic valve endocarditis when the amount of cell free DNA sequence reads derived from Bartonella bacteria associated with the prosthetic value endocarditis exceeds a threshold level. Claim 91 recites a step of comparing the amount of subsequent cell-free DNA sequence reads to the amount detected to monitor treatment response. The practitioner necessarily needs to perform a comparison in order to determine that the amount of cell free DNA sequence reads derived from Bartonella exceeds a threshold (claim 74 and 89) and is 10-100% lower than a threshold level (claim 92-93). The identifying and comparing steps encompass a mental process step which could be practiced in the mind. For example, the claims encompass embodiments in which a practitioner evaluates a subjects cell free DNA sequence reads to identifying endocarditis in the subject, the practitioner further compares the cell free DNA sequence reads to a threshold level to identify endocarditis. These steps encompass a mental process step that is an abstract idea. The claims recite a law of nature. Claim 74 and 89 recites identifying prosthetic valve endocarditis when the amount of cell free DNA sequence reads derived from Bartonella bacteria associated with the prosthetic value endocarditis exceeds a threshold level. The association of Bartonella bacteria with prosthetic value endocarditis and presence of cell free DNA sequence reads derived from Bartonella bacteria for identification of endocarditis or osteomyelitis are a natural phenomenon. These recited relationships are a natural phenomenon that exists apart from any human action. This judicial exception is not integrated into a practical application because the claims recited in the claims in addition to the judicial exception are data gathers steps that do not apply or integrate the judicial exception in any way. The claims do not include additional elements that are sufficient to amount to significantly more than the judicial exception because the steps in addition the judicial exception are data gather steps recited at a high level of generality employing techniques that were well-established, routine and conventional at the time of the invention. Here the claims includes steps of performing massively parallel sequencing on cell-free DNA from plasma samples and detecting an amount of cell free DNA sequence reads derived from Bartonella bacteria associated with prosthetic valve endocarditis. Prior to the invention, Solansky (2020, cited on IDS) and Cheng (2019, cited on IDS) teach obtaining plasma samples and performing massively parallel sequencing on cell-free DNA from plasma samples. Claim 75-76 and 79 further limit the Bartonella bacteria, thus is a field of use limitation which does not amount to significantly more. Claims 77-78 further limit the threshold and thus only limits the judicial exceptions. Claims 80-86 further limit the subject and is a field of use limitation which does not amount to significantly more. Claim 86 and 89 further recite administering a treatment regimen to the subject, however this treatment is not a particular treatment for a disease or medical condition. The recitation of a treatment regimen encompasses any and all treatments. A claim limitation can integrate a judicial exception by applying or using the judicial exception to effect a particular treatment or prophylaxis for a disease or medical condition. When evaluating this consideration, one must the following: (i) the particularity or generality of the treatment or prophylaxis limitation; (ii) whether the limitations have more than a nominal or insignificant relationship to the exception; and (iii) whether the limitations are merely extra solution activity or field of use. The steps of “administering a treatment regiment” is not particular i.e., specifically identified so that it does not encompass all applications of the judicial exception. In other words, the claims broadly encompass any and all therapy regimens. With regard to claim 90, this step further limits the endocarditis and is therefore a field of use limitation. With regard to claim 91-93 these steps further limit the thresholds and comparison and therefore limits the judicial exceptions. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 74-80, 82-84, 86, 88-93 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Solansky (Open Forumn Infect Dis, 2020, 7(suppl 1):S407, cited on IDS) Solansky teaches plasma next-generation sequencing for circulating microbial cell free DNA has utility in diagnosing and monitoring response to treatment in endocarditis. Solansky teaches blood samples were obtained prior to and after aortic value replacement in a patient with a negative endocarditis. Microbial cfDNA was extracted from plasm and NGS was performed. Solansky teaches organisms present above a predefined threshold that were reported and quantified in DNA molecules per microliter (MPM). Solansky teaches a subject with well controlled HIV infection and bioprosthetic aortic value (prosthetic valve, immunocompromised, received immunosuppressant, complete hearth value) (claims 80, 82-83) (see methods). Solansky teaches a negative blood culture (claim 84) (see methods). Solansky teaches identifying Bartonella quintana by NGS and Bartonella henselae serologies were positive (claim 75 and claim 79). Solansky teaches after 4 weeks of parenteral antibiotics, Bartonella quintana mcfDNA was decreased by 16 fold to 8813 MPM (claim 77-78, claim 86, 89-90). Solansky teaches remove of infected valve (see results) (claim 86 and 88). Solansky teaches repeating mcfDNA signal to 103 MPM following removal of valve (claim 91-93). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claims 74-93 are rejected under 35 U.S.C. 103 as being unpatentable over Downey (JPIDS, 2021:10, 213-216, published online Feb 24, 2020) in view of Kondo (2019, cited on IDS). Downey teaches identifying of B. vinsonii using next generation sequencing in patient with culture negative endocarditis. Downey teaches a subject with glomerulonephritis (see diagnosis) (claim 81) and suspected endocarditis. Downey teaches the subject was positive for B. henselae and B. quintana (see laboratory testing) (claim 79). Downey teaches performing NGS testing of blood to quantitate the Bartonella DNA signal to monitor response to antibiotic treatment (See table 1). Downey teaches MPM levels and reduction is 10% lower than threshold following treatment (claims 77-78, 91-93). Downey teaches administering doxycycline to the subject (claim 87). Downey does not teach a subject with a prosthetic valve endocarditis, B. henselae, immunocompromised, or received an immunosuppressant. Kondo teaches obtaining plasma from a patient that had fever and pulmonary valve replacement and bioprosthetic pulmonary valve replacement (fever, claim 85). Konda teaches blood cultures were negative (claim 84). Konda teaches testing blood for B. henselae (suspected cat scratch fever) (claim 79) (see case presentation). Konda teaches performing NGS of microbial cell free DNA to identify pathogen (see case presentation). Konda teaches obtaining plasma mcfDNA and performing NGS to identify alteration in prosthetic valve and endocarditis. Konda teaches removing human sequence reads and aligning remaining reads to a database including bacteria. Konda teaches identifying C. burnetti mcfDNA. Konda teaches identifying C. burnettie endocarditis and teaches MPM greater than 10,000 (see results, pg. 3) (claim 77-78). Konda teaches administering doxycycline (administering a treatment regimen including doxycycline) followed by successful PVR and graft exchange (replacement of prosthetic valve) (claims 85-90). Because the art teaches analysis of prosthetic valve endocarditis using NGS, it would have been obvious to the ordinary artisan to modify the teaching of Downey to include subjects with prosthetic values as taught by Konda. The ordinary artisan would have been motivated with an expectation of success that the methods of Downey could include subjects with prosthetic values for identification of prosthetic valve endocarditis derived from Bartonella because Konda teaches subjects with prosthetic valves with endocarditis that are positive for bacterial infection by analysis of mcf-NGS. It would have been obvious to include included subjects with fever, analysis reads of MPM thresholds greater than 10,000 and partial or complete heart valve as taught by Konda. The ordinary artisan would have been motivated to include analysis of Bartonella bacteria including henselae because Konda teaches prosthetic value endocarditis potential etiologies include Bartonella henselae. The ordinary artisan would have been motivated with a reasonable expectation of success to include analysis of prosthetic valve endocarditis by Bartonella bacteria in subjects who are immunocompromised, or received an immunosuppressant to allow for analysis of subjects with varying etiologies because mcfNGS testing allows for a specific and rapid detection of infection that is non-invasive and can complement conventional diagnostic methods when Bartonella species is considered in the differential diagnosis of culture negative endocarditis as taught by Downey. immunosuppressant to allow for analysis of subjects with varying etiologies because mcfNGS testing allows for a specific and rapid detection of infection that is non-invasive and can complement conventional diagnostic methods when Bartonella species is considered in the differential diagnosis of culture negative endocarditis as taught by Downey. Conclusion No claims are allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARAE L BAUSCH whose telephone number is (571)272-2912. The examiner can normally be reached M-F 9a-4p. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Fereydoun Sajjadi can be reached at 571-272-3311. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SARAE L BAUSCH/ Primary Examiner, Art Unit 1699
Read full office action

Prosecution Timeline

Jul 07, 2023
Application Filed
Aug 26, 2026
Non-Final Rejection mailed — §101, §102, §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12760365
Clinical and Molecular Prognostic Markers for Liver Transplantation
4y 6m to grant Granted Oct 13, 2026
Patent 12742209
METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR
3y 6m to grant Granted Sep 22, 2026
Patent 12716098
GENETIC DIAGNOSTIC TOOL FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD)
3y 9m to grant Granted Aug 25, 2026
Patent 12704506
MICROBIAL ANALYSIS WITHOUT CELL PURIFICATION
5y 4m to grant Granted Aug 11, 2026
Patent 12686890
CRISPR-CAS14A RESPONSE PHOTOELECTROCHEMICAL SENSING DETECTION METHOD AND KIT FOR DETECTING T2 TOXIN
3y 6m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
30%
Grant Probability
75%
With Interview (+45.2%)
Low
PTA Risk
Based on 615 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month